Michael T. Baker

Michael T. Baker

Auto-generated profile, based on publicly available information

Michael T. Baker

Division of Cardiology, Department of Internal Medicine (M.T.B., J.M.D.), Vanderbilt University Medical Center

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2023 in Circulation
Verified
Journal Article
Closed access
ASAeron M. Small
Aeron M. Small
GPGina M. Peloso
Gina M. Peloso
JLJason Linefsky
Jason Linefsky
JAJayashri Aragam
Jayashri Aragam
AGAshley Galloway
Ashley Galloway
COChristopher J. O’dOnnell
Christopher J. O’dOnnell
Background: Calcific aortic stenosis (CAS) is the most common valvular heart disease in older adults and has no effective preventive therapies. Genome-wide association studies (GWAS) can identify genes influencing disease and may help prioritize therapeutic targets for CAS. Methods: We performed a GWAS and gene association study of 14 451 patients with CAS and 398 544 controls in the Million Veteran Program. Replication was performed in the Million Veteran Program, Penn Medicine Biobank, Mass General Brigham Biobank, BioVU, and BioMe, totaling 12 889 cases and 348 094 controls. Causal genes were prioritized from genome-wide significant variants using polygenic priority score gene localization, expression quantitative trait locus colocalization, and nearest gene methods. CAS genetic architecture was compared with that of atherosclerotic cardiovascular disease. Causal inference for cardiometabolic biomarkers in CAS was performed using Mendelian randomization and genome-wide significant loci were characterized further through phenome-wide association study. Results: We identified 23 genome-wide significant lead variants in our GWAS representing 17 unique genomic regions. Of the 23 lead variants, 14 were significant in replication, representing 11 unique genomic regions. Five replicated genomic regions were previously known risk loci for CAS ( PALMD, TEX41, IL6, LPA, FADS ) and 6 were novel ( CEP85L, FTO, SLMAP, CELSR2, MECOM, CDAN1 ). Two novel lead variants were associated in non-White individuals ( P <0.05): rs12740374 ( CELSR2 ) in Black and Hispanic individuals and rs1522387 ( SLMAP ) in Black individuals. Of the 14 replicated lead variants, only 2 (rs10455872 [ LPA ], rs12740374 [ CELSR2 ]) were also significant in atherosclerotic cardiovascular disease GWAS. In Mendelian randomization, lipoprotein(a) and low-density lipoprotein cholesterol were both associated with CAS, but the association between low-density lipoprotein cholesterol and CAS was attenuated when adjusting for lipoprotein(a). Phenome-wide association study highlighted varying degrees of pleiotropy, including between CAS and obesity at the FTO locus. However, the FTO locus remained associated with CAS after adjusting for body mass index and maintained a significant independent effect on CAS in mediation analysis. Conclusions: We performed a multiancestry GWAS in CAS and identified 6 novel genomic regions in the disease. Secondary analyses highlighted the roles of lipid metabolism, inflammation, cellular senescence, and adiposity in the pathobiology of CAS and clarified the shared and differential genetic architectures of CAS with atherosclerotic cardiovascular diseases.

4 March 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
CRCarolina Roselli
Carolina Roselli
MYMengyao Yu
Mengyao Yu
VNVictor Nauffal
Victor Nauffal
AGAdrien Georges
Adrien Georges
QYQiong Yang
Qiong Yang
DMDavid J Milan
David J Milan
Mitral valve prolapse (MVP) is a common valvular heart disease with a prevalence of >2% in the general adult population. Despite this high incidence, there is a limited understanding of the molecular mechanism of this disease, and no medical therapy is available for this disease. We aimed to elucidate the genetic basis of MVP in order to better understand this complex disorder. We performed a meta-analysis of six genome-wide association studies that included 4884 cases and 434 649 controls. We identified 14 loci associated with MVP in our primary analysis and 2 additional loci associated with a subset of the samples that additionally underwent mitral valve surgery. Integration of epigenetic, transcriptional, and proteomic data identified candidate MVP genes including LMCD1, SPTBN1, LTBP2, TGFB2, NMB, and ALPK3. We created a polygenic risk score (PRS) for MVP and showed an improved MVP risk prediction beyond age, sex, and clinical risk factors. We identified 14 genetic loci that are associated with MVP. Multiple analyses identified candidate genes including two transforming growth factor-β signalling molecules and spectrin β. We present the first PRS for MVP that could eventually aid risk stratification of patients for MVP screening in a clinical setting. These findings advance our understanding of this common valvular heart disease and may reveal novel therapeutic targets for intervention. This study meta-analysed 4884 mitral valve prolapse (MVP) cases versus 434 649 controls, and discovered 16 genetic loci associated to MVP. Downstream analyses implicated candidate genes involved in TGF-beta signalling, cardiomyopathy and the cytoskeleton. The results from the meta-analysis were used to calculate a polygenic risk score (PRS) to aid prediction of MVP. Adding the PRS to a model with age, sex and clinical risk factors improved MVP risk prediction. Abbreviations, MVP, mitral valve prolapse, p, p-value, PRS, polygenic risk score, RF, risk factors.

29 September 2017 in Heart
Verified
Journal Article
Closed access
PDF file
BHBrandon S Hays
Brandon S Hays
MBMichael Baker
Michael Baker
ALAnnie Laib
Annie Laib
WTWei Tan
Wei Tan
SUSebastian Udholm
Sebastian Udholm
GVGruschen R Veldtman
Gruschen R Veldtman
Objective Fontan circulations have obligatory venous hypertension, depressed cardiac output and abnormal arterial elastance. Ventriculovascular coupling is known to be abnormal, but the underlying mechanisms are poorly defined. We aim to describe the histopathological features of vascular remodelling encountered in the central arteries and veins in the Fontan circulation as a possible underlying pathological representation of abnormal ventriculovascular coupling. Methods Postmortemvasculature (inferior vena cava (IVC), superior vena cava (SVC), pulmonary artery (PA), pulmonary vein (PV) and aorta) of 13 patients with a Fontan circulation (mean age 29.9 years, range 9.0–59.8 years) and 2 biventricular controls (ages 17.9 and 30.2 years) was examined. Results IVC and SVC: Eccentric and variable intimal fibromuscular proliferation occurred in 11 Fontan subjects. There was variable loss of medial smooth muscle bundles with reciprocal replacement with dense collagenous tissue. PA: Similar intimal fibromuscular proliferation was seen; however, these intimal changes were accompanied by medial thinning rather than expansion, medial myxoid degeneration and elastic alteration. PV: The PVs demonstrated intimal fibroproliferation and disorganisation of the muscular media. Aorta: The aortic lamina intima was thickened, with associated fibromuscular proliferation and elasticisation. There was also moderate lymphocytic inflammation in the aortic wall. Conclusions Vascular architectural remodelling is common in Fontan patients. The central veins demonstrate profound changes of eccentric intimal expansion and smooth muscle replacement with collagen. The pulmonary demonstrated abnormal intimal proliferation, and aortic remodelling was characterised by intima lamina thickening and a moderate degree of aortic wall inflammation.

4 October 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
APAndrew S. Perry
Andrew S. Perry
ESElliot J. Stein
Elliot J. Stein
MBMichael Biersmith
Michael Biersmith
WFWilliam F Fearon
William F Fearon
SESammy Elmariah
Sammy Elmariah
BLBrian R. Lindman
Brian R. Lindman
Background: Global longitudinal strain (GLS) is a sensitive measure of left ventricular function and a risk marker in severe aortic stenosis. We sought to determine whether biomarkers of cardiac damage (cardiac troponin) and stress (NT‐proBNP [N‐terminal pro‐B‐type natriuretic peptide]) could complement GLS to identify patients with severe aortic stenosis at highest risk. Methods and Results: From a multicenter prospective cohort of patients with symptomatic severe aortic stenosis who underwent transcatheter aortic valve implantation, we measured absolute GLS (aGLS), cardiac troponin, and NT‐proBNP at baseline in 499 patients. Left ventricular ejection fraction <50% was observed in 19% and impaired GLS (aGLS <15%) in 38%. Elevations in cardiac troponin and NT‐proBNP were present in 79% and 89% of those with impaired GLS, respectively, as compared with 63% and 60% of those with normal GLS, respectively ( P <0.001 for each). aGLS 2; P ≤0.002 for each) when the other biomarker was elevated, but not when the other biomarker was normal (interaction P =0.015). Conclusions: Among patients with symptomatic severe aortic stenosis undergoing transcatheter aortic valve implantation, elevations in circulating cardiac troponin and NT‐proBNP are more common as GLS worsens. Biomarkers of cardiac damage and stress are independently associated with mortality after transcatheter aortic valve implantation, whereas GLS is not. These findings may have implications for risk stratification of asymptomatic patients to determine optimal timing of valve replacement.

12 May 2023 in Circulation Research
Verified
Journal Article
Closed access
SHS. Neil Holby
S. Neil Holby
TRTadarro Lee Richardson
Tadarro Lee Richardson
JLJ. Lukas Laws
J. Lukas Laws
TMThomas A. McLaren
Thomas A. McLaren
JSJonathan H. Soslow
Jonathan H. Soslow
SHSean G. Hughes
Sean G. Hughes
Infection with SARS-CoV-2, the virus that causes COVID, is associated with numerous potential secondary complications. Global efforts have been dedicated to understanding the myriad potential cardiovascular sequelae which may occur during acute infection, convalescence, or recovery. Because patients often present with nonspecific symptoms and laboratory findings, cardiac imaging has emerged as an important tool for the discrimination of pulmonary and cardiovascular complications of this disease. The clinician investigating a potential COVID-related complication must account not only for the relative utility of various cardiac imaging modalities but also for the risk of infectious exposure to staff and other patients. Extraordinary clinical and scholarly efforts have brought the international medical community closer to a consensus on the appropriate indications for diagnostic cardiac imaging during this protracted pandemic. In this review, we summarize the existing literature and reference major societal guidelines to provide an overview of the indications and utility of echocardiography, nuclear imaging, cardiac computed tomography, and cardiac magnetic resonance imaging for the diagnosis of cardiovascular complications of COVID.

7 August 2022 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
KMKelly L. Mishra
Kelly L. Mishra
MBMichael T. Baker
Michael T. Baker
KSKara K. Siegrist
Kara K. Siegrist
ALAlice Liao
Alice Liao
ASAndrew E. Scanga
Andrew E. Scanga
LMLisa A. Mendes
Lisa A. Mendes